S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   170.12 (-1.49%)
MSFT   415.45 (+0.44%)
META   499.26 (-0.19%)
GOOGL   153.91 (-0.61%)
AMZN   183.51 (-0.06%)
TSLA   156.02 (-3.38%)
NVDA   869.57 (+1.11%)
AMD   163.06 (+1.71%)
NIO   3.79 (-2.57%)
BABA   69.76 (-1.22%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.01 (-1.12%)
GE   154.06 (+0.23%)
CGC   6.66 (-4.58%)
DIS   113.56 (+0.54%)
AMC   2.61 (+5.67%)
PFE   25.93 (+0.08%)
PYPL   63.66 (+0.24%)
XOM   118.77 (-0.76%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   170.12 (-1.49%)
MSFT   415.45 (+0.44%)
META   499.26 (-0.19%)
GOOGL   153.91 (-0.61%)
AMZN   183.51 (-0.06%)
TSLA   156.02 (-3.38%)
NVDA   869.57 (+1.11%)
AMD   163.06 (+1.71%)
NIO   3.79 (-2.57%)
BABA   69.76 (-1.22%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.01 (-1.12%)
GE   154.06 (+0.23%)
CGC   6.66 (-4.58%)
DIS   113.56 (+0.54%)
AMC   2.61 (+5.67%)
PFE   25.93 (+0.08%)
PYPL   63.66 (+0.24%)
XOM   118.77 (-0.76%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   170.12 (-1.49%)
MSFT   415.45 (+0.44%)
META   499.26 (-0.19%)
GOOGL   153.91 (-0.61%)
AMZN   183.51 (-0.06%)
TSLA   156.02 (-3.38%)
NVDA   869.57 (+1.11%)
AMD   163.06 (+1.71%)
NIO   3.79 (-2.57%)
BABA   69.76 (-1.22%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.01 (-1.12%)
GE   154.06 (+0.23%)
CGC   6.66 (-4.58%)
DIS   113.56 (+0.54%)
AMC   2.61 (+5.67%)
PFE   25.93 (+0.08%)
PYPL   63.66 (+0.24%)
XOM   118.77 (-0.76%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   170.12 (-1.49%)
MSFT   415.45 (+0.44%)
META   499.26 (-0.19%)
GOOGL   153.91 (-0.61%)
AMZN   183.51 (-0.06%)
TSLA   156.02 (-3.38%)
NVDA   869.57 (+1.11%)
AMD   163.06 (+1.71%)
NIO   3.79 (-2.57%)
BABA   69.76 (-1.22%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.01 (-1.12%)
GE   154.06 (+0.23%)
CGC   6.66 (-4.58%)
DIS   113.56 (+0.54%)
AMC   2.61 (+5.67%)
PFE   25.93 (+0.08%)
PYPL   63.66 (+0.24%)
XOM   118.77 (-0.76%)
Free Trial

INmune Bio (INMB) News Today

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)
Free INMB Stock Alerts
$9.46
-0.12 (-1.25%)
(As of 10:47 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
MarketBeat logoINmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest
americanbankingnews.com - April 16 at 5:34 AM
finance.yahoo.com logoINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
finance.yahoo.com - April 8 at 8:33 AM
globenewswire.com logoINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
globenewswire.com - April 8 at 8:00 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
markets.businessinsider.com - April 2 at 11:32 PM
finance.yahoo.com logoINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 12:16 PM
finance.yahoo.com logoINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
finance.yahoo.com - March 31 at 10:18 AM
seekingalpha.com logoINmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 2:42 PM
finance.yahoo.com logoINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
finance.yahoo.com - March 29 at 7:30 PM
finanznachrichten.de logoINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
finanznachrichten.de - March 29 at 9:29 AM
globenewswire.com logoINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
globenewswire.com - March 28 at 4:01 PM
globenewswire.com logoINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
globenewswire.com - March 26 at 4:01 PM
globenewswire.com logoINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
globenewswire.com - March 13 at 8:00 AM
finanznachrichten.de logoINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro
finanznachrichten.de - March 6 at 7:23 PM
markets.businessinsider.com logoBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
markets.businessinsider.com - March 6 at 7:23 PM
globenewswire.com logoINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™
globenewswire.com - March 5 at 8:00 AM
marketbeat.com logoINmune Bio (INMB) Set to Announce Earnings on Thursday
marketbeat.com - February 28 at 7:33 AM
finance.yahoo.com logoINMB Jun 2024 25.000 call
finance.yahoo.com - February 17 at 10:36 PM
finance.yahoo.com logoINMB Mar 2024 20.000 call
finance.yahoo.com - February 16 at 9:33 PM
finance.yahoo.com logoINMB Mar 2024 12.500 put
finance.yahoo.com - February 16 at 9:33 PM
finance.yahoo.com logoINMB Feb 2024 15.000 put
finance.yahoo.com - February 15 at 12:38 AM
marketbeat.com logoRhenman & Partners Asset Management AB Decreases Stock Position in INmune Bio, Inc. (NASDAQ:INMB)
marketbeat.com - February 12 at 1:00 PM
finance.yahoo.com logoINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
finance.yahoo.com - February 12 at 9:42 AM
finance.yahoo.com logoINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
finance.yahoo.com - February 7 at 12:22 PM
finance.yahoo.com logoInsiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company
finance.yahoo.com - February 4 at 10:24 AM
markets.businessinsider.com logoBuy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach
markets.businessinsider.com - February 1 at 8:23 AM
msn.com logoInmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 Enrollment
msn.com - February 1 at 1:18 AM
msn.com logoFDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trial
msn.com - January 31 at 8:17 PM
markets.businessinsider.com logoInmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program Developments
markets.businessinsider.com - January 31 at 8:17 PM
es.investing.com logoINmune Bio Inc (INMB)
es.investing.com - January 31 at 3:17 PM
bizjournals.com logoFDA lifts hold on local company's clinical trial for Alzheimer's drug
bizjournals.com - January 31 at 3:17 PM
finanznachrichten.de logoINmune Bio, Inc.: INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program
finanznachrichten.de - January 30 at 7:58 PM
marketwatch.com logoFDA Lifts Clinical Hold on INmune Bio Alzheimer's Program
marketwatch.com - January 30 at 9:57 AM
tmcnet.com logoINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program
tmcnet.com - January 30 at 9:57 AM
markets.businessinsider.com logoINmune Bio: FDA Removes Clinical Hold For Alzheimer's Disease Program
markets.businessinsider.com - January 30 at 9:57 AM
finance.yahoo.com logoINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
finance.yahoo.com - January 30 at 9:57 AM
finance.yahoo.com logoELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
finance.yahoo.com - January 24 at 5:06 AM
benzinga.com logoWhy Elevai Labs Stock Is Trading Higher
benzinga.com - January 16 at 1:35 PM
markets.businessinsider.com logoBuy Rating Affirmed for INmune Bio Amid Progress in Cancer Therapy Trials and Financial Stability
markets.businessinsider.com - January 4 at 10:26 AM
seekingalpha.com logoINmune Bio: Caution Still Warranted But Upgrading To Hold
seekingalpha.com - January 4 at 10:26 AM
finance.yahoo.com logoINmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - January 2 at 8:48 AM
bizjournals.com logoLocal company's clinical trial for Alzheimer’s drug put on hold by FDA
bizjournals.com - December 28 at 2:35 PM
markets.businessinsider.com logoInmune Bio’s Stock Poised for Growth on Anticipated Regulatory Milestones and Clinical Trial Progress
markets.businessinsider.com - December 21 at 7:57 PM
finanznachrichten.de logoINmune Bio, Inc.: INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
finanznachrichten.de - December 21 at 9:56 AM
marketwatch.com logoINmune Bio Alzheimer's Treatment Study to Remain on Clinical Hold
marketwatch.com - December 18 at 5:15 PM
msn.com logoINmune says Alzheimer's study should finish on time despite FDA hold
msn.com - December 18 at 5:15 PM
finance.yahoo.com logoINmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
finance.yahoo.com - December 18 at 5:15 PM
markets.businessinsider.com logoBuy Rating for Inmune Bio Backed by Promising Therapeutic Developments and Regulatory Progress
markets.businessinsider.com - December 1 at 8:22 AM
finance.yahoo.com logoINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
finance.yahoo.com - November 29 at 8:09 AM
finance.yahoo.com logoINmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
finance.yahoo.com - November 27 at 8:09 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Inmune Bio (INMB) and Guardant Health (GH)
markets.businessinsider.com - November 16 at 10:11 AM
Get INmune Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.

REVEALED: Elon Musk’s Secret A.I. Facility? (Ad)

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

INMB Media Mentions By Week

INMB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INMB
News Sentiment
▼
0.44

0.66
▲
Average
Medical
News Sentiment

INMB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INMB Articles
This Week
▼
3

1
▲
INMB Articles
Average Week

Get INmune Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:INMB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings
The #1 Crypto for 2024
InvestorPlace